Loading, Please Wait...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at two media events through the end of the year.
David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene will participate in a panel fireside chat at the Atlantic’s People v. Cancer event called “Can Immunotherapy Scale Up?” on November 12, 2019. Arie Belldegrun, M.D., FACS, Executive Chairman and Co-Founder of Allogene will present during the lunchtime keynote at the Cell Therapy & the Potential to Revolutionize the Future of Cancer Treatment on November 21, 2019 on “Cell Therapy & the Potential to Revolutionize the Future of Cancer Treatment”. Neither presentation will be webcast.
The Atlantic’s People v. Cancer
November 12, 2019
New York, NY
Cell Therapy & the Potential to Revolutionize the Future of Cancer Treatment
November 21, 2019
Allogene Therapeutics will also be presenting at three investor conferences through the end of the year. The investor presentations will be webcast and made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Stifel 2019 Healthcare Conference
Tuesday, November 19, 2019 at 11:25 AM PT/2:25 PM ET
New York City, NY
Jefferies 2019 London Healthcare Conference
November 20, 2019 at 12:40 AM PT/3:40 AM ET
Piper Jaffray 31st Annual Healthcare Conference
December 4, 2019 at 6:00 AM PT/9:00 AM ET
New York City, NY
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended September 30, 2019. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Allogene Media/Investor Contact:
Chief Communications Officer